Home › Trials › NCT07282600

Eloralintide for weight loss in adults with overweight or obesity and type 2 diabetes

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

Phase 3 Interventional Eli Lilly and Company · NCT07282600

This study will test whether eloralintide helps adults with overweight or obesity and type 2 diabetes lose more weight than a placebo over about 75 weeks.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment1035 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Locations159 sites (Birmingham, Alabama and 158 other locations)
Trial IDNCT07282600 on ClinicalTrials.gov

What this trial studies

This Phase 3 interventional study gives participants either eloralintide or a matching placebo and follows them for roughly 75 weeks to measure body weight change and safety outcomes. Eligible participants must have type 2 diabetes, be on a stable diabetes treatment for at least 90 days, have a BMI of 27 kg/m2 or higher, and have stable weight in the prior 90 days. People who recently used GLP-1/GIP agents, amylin analogs, or insulin, or who had recent major cardiovascular events, are excluded, as are those with recent or planned surgical/device obesity interventions. The primary focus is on body weight reduction with concurrent monitoring of diabetes control and adverse events.

Who should consider this trial

Good fit: Adults with type 2 diabetes who have had stable diabetes treatment for ≥90 days, a BMI ≥27 kg/m2, and stable body weight for the prior 90 days, who are not using GLP-1/GIP agents, amylin analogs, or insulin and who have no recent major cardiovascular events, are the ideal candidates.

Not a fit: People with type 1 diabetes, recent heart attack or stroke, recent use of excluded antihyperglycemic drugs (GLP-1/GIP agents, amylin analogs, or insulin), or recent/planned bariatric or device-based obesity procedures are unlikely to qualify or benefit from this study.

Why it matters

Potential benefit: If successful, eloralintide could help people with overweight or obesity and type 2 diabetes achieve clinically meaningful weight loss and potentially improve blood sugar control.

How similar studies have performed: Other agents targeting incretin and related pathways (for example GLP-1 and dual GIP/GLP-1 drugs) have produced substantial weight loss in people with type 2 diabetes, but eloralintide itself is currently being tested in Phase 3 to confirm efficacy and safety.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have type 2 diabetes
* Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
* Have a BMI ≥ 27 kg/m2
* Have a stable body weight (\<5% body weight change) for 90 days prior to screening

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following antihyperglycemic medications within 90 days before screening:

  * amylin analogs
  * glucagon-like peptide-1 (GLP-1) receptor agonists
  * glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
  * insulin
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Where this trial is running

Birmingham, Alabama and 158 other locations

+109 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions OverweightObesityType 2 Diabetes
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.